Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.70 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.68 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.68 |
| ▸ | P2RY10 | O00398 | 6/20 | 0.59 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL340007 | 1.00 | LPAR3 (0.70) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL8374139 | 0.98 | LPAR3 (0.68) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL21957628 | 0.95 | LPAR3 (0.79) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL158207 | 0.95 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL146977 | 0.95 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL146569 | 0.95 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL145057 | 0.95 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL6120935 | 0.95 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| SCHEMBL6316146 | 0.95 | LPAR3 (0.74) | LPAR3LPAR2LPAR1P2RY10GPR34 | |
| Triethyl Phosphate SCHEMBL21957626 | 0.94 | LPAR3 (0.66) | LPAR3LPAR2LPAR1P2RY10GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2025-02-13 | — | — | US | claimed |
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | claimed |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | ARCUTIS BIOTHERAPEUTICS, INC. (US) | 2024-01-25 | — | — | US | claimed |
| EP-0083957-B1 | ORGANIC GELS AND METHOD OF CLEANING PIPELINES BY USING SAID GELS | THE DOW CHEMICAL COMPANY (US) | 1988-08-24 | — | — | EP | claimed |
| US-4537700-A | NONPOLAR SOLVENT, ETHYL OLEYL PHOSPHATE, ALKALI METAL ALUMINATE; PIGS FOR PIPELINE CLEANING | THE DOW CHEMICAL COMPANY (US) | 1985-08-27 | — | — | US | claimed |
| US-4473408-A | SOLVENT WITH GELLING AMOUNT OF ALKYL OLEYL PHOSPHATE AND ALKALI METAL ALUMINATES | THE DOW CHEMICAL COMPANY (US) | 1984-09-25 | — | — | US | claimed |
| EP-0083957-A1 | Organic gels and method of cleaning pipelines by using said gels | THE DOW CHEMICAL COMPANY (US) | 1983-07-20 | — | — | EP | claimed |
| CN-119212706-A | Self-preserving topical pharmaceutical compositions comprising diethylene glycol monoethyl ether | 阿尔库缇斯生物疗法股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119097625-A | Method and formulation for improving skin permeation lag time of roflumilast | 阿尔库缇斯生物疗法股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-114641297-B | Treatment of skin conditions using high krafft temperature anionic surfactants | 阿尔库缇斯生物疗法股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| CN-113677481-B | Anionic polishing pad formed by printing process | 应用材料公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20230265268-A1 | THERMOPLASTIC ELASTOMER COMPOSITION | POLYMAX THERMOPLASTIC ELASTOMERS, LLC | 2023-08-24 | — | — | US | disclosed |
| EP-3656897-B1 | DILUTED SOLUTION OF SYNTHETIC FIBER TREATMENT AGENT, AND METHOD FOR MANUFACTURING SYNTHETIC FIBERS | TAKEMOTO OIL & FAT CO LTD (JP) | 2023-01-04 | — | — | EP | disclosed |
| US-20020055562-A1 | Gel compositions | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2002-05-09 | — | — | US | disclosed |
| US-5202035-A | Liquid aluminum phosphate salt gelling agent | NALCO CHEMICAL COMPANY (US) | 1993-04-13 | — | — | US | disclosed |
| US-5110485-A | Fracturing subterranean formations; enhanced oil recovery | NALCO CHEMICAL COMPANY (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0083957-B1 | ORGANIC GELS AND METHOD OF CLEANING PIPELINES BY USING SAID GELS | THE DOW CHEMICAL COMPANY (US) | 1988-08-24 | — | — | EP | disclosed |
| US-4537700-A | NONPOLAR SOLVENT, ETHYL OLEYL PHOSPHATE, ALKALI METAL ALUMINATE; PIGS FOR PIPELINE CLEANING | THE DOW CHEMICAL COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| US-4473408-A | SOLVENT WITH GELLING AMOUNT OF ALKYL OLEYL PHOSPHATE AND ALKALI METAL ALUMINATES | THE DOW CHEMICAL COMPANY (US) | 1984-09-25 | — | — | US | disclosed |
| EP-0083957-A1 | Organic gels and method of cleaning pipelines by using said gels | THE DOW CHEMICAL COMPANY (US) | 1983-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042487-B2 | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors | PDE12, PDE4A, SMPD4 | LPAR3 1226/4885LPAR2 1438/4885LPAR1 1148/4885 |
| US-20240024300-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | LPAR3 1226/4885LPAR2 1438/4885LPAR1 1148/4885 |
| US-20250049771-A1 | METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORS | PDE12, PDE4A, SMPD4 | LPAR3 1226/4885LPAR2 1438/4885LPAR1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.